• Biontech SE BNTX.OQ reported quarterly adjusted earnings of €1.08​​ per share for the quarter ended December 31, lower than the same quarter last year, when the company reported EPS of €1.90. The mean expectation of fifteen analysts for the quarter was for earnings of 33 cents per share. Wall Street expected results to range from €-1.19 to €2.10 per share.

• Revenue fell 19.5% to €1.19 billion from a year ago; analysts expected €1.09 billion.

• Biontech SE's reported EPS for the quarter was €1.08​.

• The company reported quarterly net income of €259.5 million.

• Biontech SE shares had fallen by 4.5% this quarter.

FORECAST CHANGES

• The mean earnings estimate of analysts had fallen by about 34.6% in the last three months.​

• In the last 30 days, there have been no earnings estimate revisions by analysts covering the company.

RECOMMENDATIONS

• The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 16 "strong buy" or "buy," 5 "hold" and no "sell" or "strong sell."

• The average consensus recommendation for the biotechnology & medical research peer group is also "buy"

Wall Street's median 12-month price target for Biontech SE is $136.50

This summary was machine generated from LSEG data March 10 at 03:05 p.m. UTC. ​All figures in euros unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)